XML 36 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Business Segment Information
 12 Months Ended
Mar. 31, 2023
Notes To Financial Statements [Abstract]  
Business Segment Information
11.BUSINESS SEGMENT INFORMATION
We operate and report our financial information in four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences and Dental. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income.
Our Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Our products and services range from infection prevention consumables and capital equipment, as well as services to maintain that equipment; to the repair of re-usable procedural instruments; to outsourced instrument reprocessing services. In addition, our procedural solutions also include endoscopy accessories and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas.
Our Applied Sterilization Technologies ("AST") segment is a third-party service provider for contract sterilization, as well as testing services needed to validate sterility services for medical device and pharmaceutical manufacturers. Our technology-neutral offering supports Customers every step of the way, from testing through sterilization.
Our Life Sciences segment provides a comprehensive offering of products and services that support pharmaceutical manufacturing, primarily for vaccine and other biopharma Customers focused on aseptic manufacturing. These solutions include a full suite of consumable products, equipment maintenance and specialty services, and capital equipment.
Our Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems.
We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. Certain prior period costs were reallocated from the Healthcare segment to Corporate to conform with current year presentation. The prior period segment operating income measure has been recast for comparability.
For the year ended March 31, 2023, revenues from a single Customer did not represent ten percent or more of the Healthcare, AST or Life Sciences segment revenues. Three Customers collectively and consistently account for more than 40.0% of our Dental segment revenue. The percentage associated with these three Customers collectively in any one period may vary due to the buying patterns of these three Customers as well as other Dental Customers. These three Customers collectively accounted for approximately 47.4% and 45.1% of our Dental segment revenues for the years ended March 31, 2023 and 2022, respectively.
Information regarding our segments is presented in the following tables.
Years Ended March 31,202320222021
Revenues:
Healthcare $3,085,131 $2,845,467 $1,954,055 
Applied Sterilization Technologies914,431 852,972 685,912 
Life Sciences536,704 524,964 467,552 
Dental421,573 361,661 — 
Total revenues$4,957,839 $4,585,064 $3,107,519 
Operating income (loss):
Healthcare 706,020 649,704 427,089 
Applied Sterilization Technologies429,020 410,101 310,648 
Life Sciences210,225 216,188 180,796 
Dental89,527 84,441 — 
Corporate(264,791)(283,665)(219,153)
Total operating income before adjustments$1,170,001 $1,076,769 $699,380 
Less: Adjustments
Amortization of acquired intangible assets (1)
376,822 366,434 83,892 
Acquisition and integration related charges (2)
24,196 205,788 35,634 
Tax restructuring costs (3)
661 301 1,592 
Gain on fair value adjustment of acquisition related contingent consideration (1)
(3,100)(2,350)(500)
 Net (gain) loss on divestiture of businesses (1)
(67)(874)2,030 
Amortization of inventory and property "step up" to fair value (1)
12,254 81,804 5,600 
COVID-19 incremental costs (4)
— — 25,793 
Restructuring charges (credit) (5)
485 48 (3,029)
Goodwill impairment loss (6)
490,565 — — 
Total operating income$268,185 $425,618 $548,368 
(1) For more information regarding our recent acquisitions and divestitures, refer to Note 2 titled, "Business Acquisitions and Divestitures."
(2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.
(3) Costs incurred in tax restructuring.
(4) COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.
(5) For more information regarding our restructuring efforts, refer to our Annual Report on Form 10-K for the year ended March 31, 2021, dated May 28, 2021.
(6) For more information regarding our goodwill impairment loss, refer to Note 3 titled, "Goodwill and Intangible Assets."

Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments.
Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together.
March 31,20232022
Assets
Healthcare and Life Sciences$6,538,270 $6,604,893 
Applied Sterilization Technologies3,124,341 3,053,116 
Dental1,159,228 1,765,585 
Total assets$10,821,839 $11,423,594 
Years Ended March 31,202320222021
Capital Expenditures
Healthcare and Life Sciences$98,585 $84,487 $74,446 
Applied Sterilization Technologies253,914 198,350 164,816 
Dental9,470 4,726 — 
Total Capital Expenditures$361,969 $287,563 $239,262 
Depreciation, Depletion, and Amortization (1)
Healthcare and Life Sciences $306,377 $316,222 $106,266 
Applied Sterilization Technologies 116,153 115,925 112,971 
Dental130,367 120,957 — 
Total Depreciation, Depletion, and Amortization$552,897 $553,104 $219,237 
(1) Fiscal 2022 totals include approximately $229,052, $35,531 and $113,099 for Healthcare and Life Sciences, Applied Sterilization Technologies, and Dental, respectively, of amortization of acquired intangible assets and amortization of property "step-up" to fair value. For more information regarding our recent acquisitions and divestitures see Note 2 titled, "Business Acquisitions and Divestitures."
Financial information for each of our United States and international geographic areas is presented in the following table. Revenues are based on the location of these operations and their Customers. Property, plant, and equipment, net are those assets that are identified within the operations in each geographic area.
March 31,20232022
Property, Plant, and Equipment, Net
Ireland$60,570 $60,275 
United States946,930 881,057 
Other locations698,012 611,244 
Property, Plant, and Equipment, Net$1,705,512 $1,552,576 
Years Ended March 31,202320222021
Revenues:
Ireland$74,463 $82,011 $71,905 
United States3,586,486 3,228,864 2,227,038 
Other locations1,296,890 1,274,189 808,576 
Total Revenues$4,957,839 $4,585,064 $3,107,519 
Years Ended March 31,202320222021
Healthcare:
Capital equipment896,590 $782,505 $588,864 
Consumables1,050,316 1,004,605 510,946 
Service1,138,225 1,058,357 854,245 
Total Healthcare Revenues $3,085,131 $2,845,467 $1,954,055 
Applied Sterilization Technologies:
Capital equipment$26,460 $24,394 $— 
Service$887,971 $828,578 $685,912 
Total Applied Sterilization Technologies Service Revenues$914,431 $852,972 $685,912 
Life Sciences:
Capital equipment$147,420 $142,281 $128,356 
Consumables241,114 239,365 215,005 
Service148,170 143,318 124,191 
Total Life Sciences Revenues$536,704 524,964 467,552 
Dental Revenues$421,573 $361,661 $— 
Total Revenues$4,957,839 $4,585,064 $3,107,519